This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Santen Pharmaceutical Co., Ltd.
Drug Names(s): DE-101, CS-011
Description: CS-011 is a PPAR gamma agonist, with a high affinity for the receptor.
Deal Structure: In October 2005, Daichi Sankyo granted Santen exclusive rights to develop, manufacture and market CS-011 (rivoglitazone) as a treatment for conjuctival epithelial disorders.
Partners: Daiichi Sankyo Co., Ltd.
Additional information available to subscribers only: